natgillin/translations-raw huggingface dataset:
Farmakokinetiske undersøgelser med doxazosin depottabletter hos ældre har vist, at der ikke er signifikante ændringer sammenlignet med yngre patienter. 
Pharmacokinetic studies with doxazosin in the elderly have shown no significant alterations compared to younger patients.
Peak plasmaniveauer er omkring en tredjedel af niveauet opnået efter administration af doxazosin tabletter med umiddelbar frigivelse. 
Peak plasma levels are approximately one third of those of the same dose of immediate release doxazosin tablets.
Hvis De holder op med at tage Doxagamma 4 mg depottabletter og dermed forbundne navne Lad være med pludselig at holde op med at tage Deres medicin, da det kan medføre alvorlige ændringer i Deres blodtryk. 
If you stop taking Doxagamma 4 mg prolonged release tablets and associated names Do not suddenly stop taking your medicine as this may cause serious changes in your blood pressure.
Æsker med 10, 20, 28, 30, 50, 56, 60, 90, 98, 100, 140 (10x14) tabletter Kalenderpakninger med 28 og 98 depottabletter Enhedsdoseringspakning med 50 x 1 
Pack sizes: 10, 20, 28, 30, 50, 56, 60, 90, 98, 100, 140 (10 x 14) tablets Calendar packs of 28 and 98
Det Forenede Kongerige Tlf.: 00 44 1707 853000 
UK Tel: 00 44 1707 853000
Denne indlægsseddel blev senest godkendt den [Udfyldes national]. 
This leaflet was last approved in [To be completed nationally].
- De øvrige indholdsstoffer er makrogol, mikrokrystallinsk cellulose, povidon, 
- The other ingredients are macrogol, microcrystalline cellulose, povidone, butylhydroxytoluene
Det Forenede Kongerige Tlf.: 00 44 1707 853000 Fax: 00 44 1707 650734 
UK Tel: 00 44 1707 853000 Fax: 00 44 1707 650734
DERMED FORBUNDNE NAVNE: 
ASSOCIATED NAMES
• Medicin, der indeholder dopamin, metaraminol, methoxamin, adrenalin (epinefrin), hoste- og forkølelsesmidler, der kan indeholde efedrin, fenylefrin 
• medicine containing Dopamine, Metaraminol, Methoxamine, Adrenaline (Epinephrine) cough and cold remedies as they may contain Ephedrine, Phenylephrine.
Farmakokinetiske undersøgelser med doxazosin hos patienter med nedsat nyrefunktion viste heller ikke nogen signifikante ændringer sammenlignet med patienter med normal nyrefunktion. 
Pharmacokinetic studies with doxazosin in patients with renal impairment also showed no significant alterations compared to patients with normal renal function.
Hovedpine, svimmelhed, bevidstløshed, synkope, dyspnøe, hypotension, palpitationer, takykardi, arytmi. 
Headache, dizziness, unconsciousness, syncope, dyspnoea, hypotension, palpitation, tachycardia, arrhythmia.
Doxazosin bør gives med forsigtighed til patienter med følgende akutte hjertesygdomme: Lungeødem som et resultat af aorta- eller mitralstenose, hjertesvigt ved højt output, højresidig hjertesvigt som et resultat af lungeemboli, perikardial effusion og venstresidig ventrikulær hjerteinsufficiens med lavt fyldningstryk. 
Doxazosin should be administered with caution in patients with the following acute heart diseases: Pulmonary oedema as a result of aortic or mitral stenosis, heart failure at high output, right sided heart failure as a result of pulmonary embolism or pericardiac effusion and left sided ventricular heart insufficiency with low filling pressure.
Om nødvendigt kan dosis øges til 8 mg doxazosin én gang daglig. 
If necessary, the dosage may be increased to 8 mg doxazosin once daily.
Alternativt skal amning stoppes, hvis behandling med Doxagamma 4 mg depottabletter og dermed forbundne navne er uundgåelig. 
Alternatively, breastfeeding must be stopped, if treatment with Doxagamma 4 mg prolonged release tablets and associated names is unavoidable.
Den sædvanlige startdosis er én Doxagamma 4 mg depottabletter og dermed forbundne navne tablet én gang daglig. 
The usual starting dose is one Doxagamma 4 mg prolonged release tablets and associated names tablet once a day.
Doxagamma 4 mg depottabletter og dermed forbundne navne har moderat indflydelse på evnen til at køre bi log betjene maskiner, især i begyndelsen af behandlingen. 
Doxagamma 4 mg prolonged release tablets and associated names has moderate influence on the ability to drive and use machines, especially at the beginning of therapy.
Bivirkningsprofilen i kliniske afprøvninger hos patienter med benign prostatahyperplasi svarede til den, der ses ved hypertension. 
The majority of the adverse reactions were transient The adverse reaction profile in clinical trials with patients with benign prostatic hyperplasia corresponded to the one seen in hypertension.
Symptomatisk behandling af prostatahyperplasi: 
Symptomatic treatment of prostatic hyperplasia:
Da der ikke er nogen ændring i farmakokinetikken hos patienter med nedsat nyrefunktion, og da der ikke er nogen tegn på, at doxazosin forværrer eksisterende nedsat nyrefunktion, kan normal dosering generelt anvendes til disse patienter. 
Patients with renal impairment: Since there is no change in pharmacokinetics in patients with impaired renal function, and since there are no signs that doxazosin aggravates existing renal impairment, the usual dose can be used in these patients.
Patienter behandlet med doxazosin tabletter med umiddelbar frigivelse mod hypertension kan overføres til Doxagamma 4 mg depottabletter og dermed forbundne navne, og dosis titreret opad efter behov, mens virkning og tolerans bibeholdes 
Patients treated with immediate release doxazosin tablets against hypertension can be transferred to Doxagamma 4 mg prolonged release tablets and associated names and the dose titrated upwards as needed, while maintaining effect and tolerability.
Forekomsten af bivirkninger skyldes hovedsagelig lægemidlets farmakologiske egenskaber, og hovedparten af bivirkningerne var forbigående. 
The occurrence of adverse reactions are mainly due to the pharmacological properties of the medicinal product.
Hvide, runde bikonvekse tabletter med påtrykt “DL” på den ene side. 
White, round, biconvex tablets with bossing “DL”
Doxazosin er blevet administreret sammen med thiaziddiuretika, furosemid, beta-blokerende midler, antibiotika, orale hypoglykæmiske midler, urikosuriske midler eller antikoagulantia uden bivirkningersreaktioner. 
Doxazosin has been administered together with thiazide diuretics, furosemide, beta-blocking agents, antibiotics, oral hypoglycaemic agents, uricosuric agents, or anticoagulants without adverse drug interactions.
Til behandling af hypertension kan Deres læge give Dem anden medicin, der skal tages sammen med Doxagamma 4 mg depottabletter og dermed forbundne navne. 
To treat hypertension, your doctor may give you another medicine to take along with Doxagamma 4 mg prolonged release tablets and associated names .
Doxagamma 4 mg depottabletter og dermed forbundne navne bør ikke anvendes under graviditet, medmindre der er et klart behov. 
Doxagamma 4 mg prolonged release tablets and associated names should not be used during pregnancy unless clearly needed.
Hvis De glemmer at tage Doxagamma 4 mg depottabletter og dermed forbundne navne Tag den, så snart De kommer i tanke om den. 
If you forget to take Doxagamma 4 mg prolonged release tablets and associated names Take it as soon as you remember.
Doxagamma 4 mg depottabletter og dermed forbundne navne kan også gives til mænd, der lider af en forstørret prostatakirtel, da det kan afslappe musklerne og dermed tillade urinen at passerer lettere 
Doxagamma 4 mg prolonged release tablets and associated names can also be given to men suffering from an enlarged prostate gland, as it can relax the muscles allowing urine to be passed more easily.
Doxagamma 4 mg depottabletter og dermed forbundne navne kan behandle forhøjet blodtryk (hypertension) ved at afslappe blodkarrene i kroppen og sænke blodtrykket. 
Doxagamma 4 mg prolonged release tablets and associated names can treat high blood pressure (hypertension) by relaxing the blood vessels in the body and lowering blood pressure.
De farmakokinetiske egenskaber ved doxazosin i Doxagamma 4 mg depottabletter og dermed forbundne navne leder til en mindre variation i plasmaniveauer. 
The pharmacokinetic properties of doxazosin in Doxagamma 4 mg prolonged release tablets and associated names lead to a minor variation in plasma levels.
Usædvanlig: Mareridt, hukommelsestab, følelsesmæssig ustabilitet Sjælden: Depression, agitation 
Uncommon: nightmares, amnesia, emotional instability Rare: depression, agitation
Doxagamma 4 mg depottabletter og dermed forbundne navne tabletter er hvide, runde, bikonvekse tabletter med “DL” påtrykt. 
Doxagamma 4 mg prolonged release tablets and associated names tablets are white, round, biconvex tablets with bossing “DL”.
Sygdomme i det ydre og indre øre: Usædvanlig: Tinnitus 
Ear and labyrinth disorders: Uncommon: tinnitus
Administration af Doxagamma 4 mg depottabletter og dermed forbundne navne til patienter med prostatahyperplasi resulterer i en signifikant forbedring af urodynamikken og symptomer som et resultat af en selektiv blokade af alfa-adrenoreceptorer lokaliseret prostatas muskelstroma, kapsel og hals. 
Administration of Doxagamma 4 mg prolonged release tablets and associated names to patients with prostatic hyperplasia results in a significant improvement in urodynamics and symptoms as a result of a selective blockade of alpha-adrenoceptors located in the prostatic muscular stroma, capsule and bladder neck.
Doxagamma 4 mg depottabletter og dermed forbundne navne vil sandsynligvis ikke påvirke Deres blodtryk, medmindre De lider af hypertension. 
Doxagamma 4 mg prolonged release tablets and associated names is unlikely to affect your blood pressure unless you suffer from hypertension.
Peak/bølgedalsratio for Doxagamma 4 mg depottabletter og dermed forbundne navne er mindre end halvdelen af den for doxazosin tabletter med umiddelbar frigivelse. 
Peak/trough ratio of Doxagamma 4 mg prolonged release tablets and associated names is less than half that of immediate release doxazosin tablets.
Henover det anbefalede doseringsområde har Doxagamma 4 mg depottabletterne og dermed forbundne navne kun lille eller ingen virkning på blodtrykket hos normotensive patienter med benign prostatahyperplasi (BPH). 
Throughout the recommended dosage range, Doxagamma 4 mg prolonged release tablets and associated names has only a minor or no effect on blood pressure in normotensive benign prostatic hyperplasia (BPH) patients.
10 depottabletter 20 depottabletter 28 depottabletter 30 depottabletter 50 depottabletter 56 depottabletter 60 depottabletter 90 depottabletter 98 depottabletter 100 depottabletter 140 depottabletter 
10 prolonged-release tablets 20 prolonged-release tablets 28 prolonged-release tablets 30 prolonged-release tablets 50 prolonged-release tablets 56 prolonged-release tablets 60 prolonged-release tablets 90 prolonged-release tablets 98 prolonged-release tablets 100 prolonged-release tablets 140 prolonged-release tablets
2 KVALITATIV OG KVANTITATIV SAMMENSÆTNING Én depottablet indeholder 4 mg doxazosin (som mesilat). 
2 QUALITATIVE AND QUANTITATIVE COMPOSITION One prolonged-release tablet contains 4 mg doxazosin (as mesilate).
Sædvanligvis 4 mg doxazosin én gang daglig. 
Adults: Usually 4 mg doxazosin once daily.
Doxagamma 4 mg depottabletter og dermed forbundne navne kan anvendes til ved benign prostatahyperplasi (BPH) patienter, der er enten hypertensive eller normotensive, da ændringer i blodtrykket hos normotensive patienter er klinisk usignifikant. 
Doxagamma 4 mg prolonged release tablets and associated names may be used in benign prostatic hyperplasia (BPH) patients who are either hypertensive or normotensive, as the blood pressure changes in normotensive patients are clinically insignificant.
Sygdomme i åndedrætsorganer, brysthule og mediastinum: Almindelig: Dyspnøe, rhinit 
Respiratory, thoracic and mediastinal disorders: Common: dyspnoea, rhinitis
Doxagamma 4 mg depottabletter og dermed forbundne navne anbefales ikke til patienter under 18 år gamle. 
Children and adolescents: Doxagamma 4 mg prolonged release tablets and associated names are not recommended for patients under the age of 18 years.
Doxagamma 4 mg depottabletter og dermed forbundne navne kan anvendes som monoterapi eller i kombination med andre lægemidler, f.eks. et thiaziddiuretikum, et beta-adrenoreceptorblokerende middel, en calciumantagonist eller en ACE-hæmmer. 
Doxagamma 4 mg prolonged release tablets and associated names can be used as sole agent or in combination with another medicinal product e.g. a thiazide diuretic, beta-adrenoceptor blocking agent, calcium antagonist or an ACE-inhibitor.
Almindelig: Palpitationer, brystsmerter Usædvanlig: Arytmi, angina pectoris, bradykardi, takykardi, myokardieinfarkt 
Uncommon: arrhythmia, angina pectoris, bradycardia, tachycardia, myocardial infarction
Administration af Doxagamma 4 mg depottabletter og dermed forbundne navne hos hypertensive patienter medfører en klinisk signifikant reduktion af blodtrykket som et resultat af en reduktion i den systemiske vaskulære modstand. 
Administration of Doxagamma 4 mg prolonged release tablets and associated names in hypertensive patients causes a clinically significant reduction in blood pressure as a result of a reduction in systemic vascular resistance.
Symptomatisk behandling af benign prostatahyperplasi. 
- Essential hypertension - Symptomatic treatment of benign prostatic hyperplasia.
5 HVORDAN DE OPBEVARER DOXAGAMMA 4 MG DEPOTTABLETTER OG 
5 HOW TO STORE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND
Doxazosin bør gives med forsigtighed til patienter med tegn på lettere til moderat nedsat leverfunktion (se pkt. 
Doxazosin should be administered with caution in patients with signs of mild to moderate hepatic impairment (see section 5.2).
Usædvanlig: Alopecia, ødem i ansigtet/generelt ødem Sjælden: Udslæt, pruritus, purpura 
Uncommon: alopecia, oedema of the face/general oedema Rare: rash, pruritus, purpura
Hvad Doxagamma 4 mg depottabletter og dermed forbundne navne indeholder - Det aktive stof er 4 mg doxazosin som doxazosinmesilat). 
What Doxagamma 4 mg prolonged release tablets and associated names contains - The active substance is 4 mg of doxazosin as doxazosin mesilate.
Doxazosin bliver omfattende metaboliseret med <5% udskilt som uændret produkt Doxazosin bliver primært metaboliseret ved O-demethylering og hydroxylering. 
Doxazosin is extensively metabolised with <5% excreted as unchanged product.
Almindelig: Muskelkramper, træthed, malaise, hovedpine, somnolens Usædvanlig: Tremor, muskelstivhed Sjælden: Paræstesi 
Common: muscle cramps, fatigue, malaise, headache, somnolence Uncommon: tremor, muscular stiffness Rare: paraesthesia
Hver depottablet indeholder 4 mg doxazosin (som mesilat). 
Each prolonged-release tablet contains 4 mg of doxazosin (as mesylate).
De må ikke tage Doxagamma 4 mg depottabletter og dermed forbundne navne, hvis De er gravid eller ammer. 
Do not take Doxagamma 4 mg prolonged release tablets and associated names if you are pregnant or breast-feeding.
Almindelig: Konstipation, dyspepsi Usædvanlig: Anorexi, øget appetit, smagsforstyrrelser Sjælden: Abdominalt ubehag, diaré, opkastning 
Common: constipation, dyspepsia Uncommon: anorexia, increased appetite, taste disturbances Rare: abdominal discomfort, diarrhoea, vomiting
Undersøgelse af gravide kaniner og rotter ved daglige doseringer, der resulterede i plasmakoncentrationer på henholdsvis 4 og 10 gange den humane eksponering (Cmax og AUC), afslørede ikke bevis for skade på føtus. 
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenicity Studies in pregnant rabbits and rats at daily doses resulting in plasma concentrations 4 and 10 times the human exposure (Cmax and AUC), respectively, revealed no evidence of harm to the foetus.
Almindelig: Akkomoderingsforstyrrelser Usædvanlig: Tåreflåd, fotofobi Sjælden: Sløret syn 
Common: accomodation disturbances Uncommon: lacrimation, photophobia Rare: blurred vision
Sygdomme i bevægeapparatet og bindevæv: Usædvanlig: Muskelsmerter, arthralgi, muskelsvaghed 
Musculoskeletal, connective tissue and bone disorders: Uncommon: muscular pain, arthralgia, muscle weakness
Doxagamma 4 mg depottabletter og dermed forbundne navne kan tages med eller uden mad. 
Doxagamma 4 mg prolonged release tablets and associated names can be taken with or without food.
Usædvanlige bivirkninger,der ses hos færre end 1 patient ud af 1.000, men hos færre end 1 ud af 100 patienter, omfatter: Opsvulmen af of ansigt og krop, følelse af svaghed, kolde fingre og tær, svimmelhed ved at stå op, en hurtig eller uregelmæssig hjerterytme, en langsom hjerterytme, angina, kraftige brystsmerter, besvær med vejrtrækningen, tremor, muskelstivhed, svaghed eller smerter, smertende eller opsvulmede led, ændring i appetitten, hårtab, næseblod, hoste, ondt i opsvulmet hals, lave kaliunniveauer, følelse af tørst, podagra, mareridt, hukommelsestab, humørskift, tab af blærekontrol, eller mindre hyppig trang til at lade vandet, ringen for ørerne og smagsændringer. 
Uncommon effects, seen in more than 1 out of 1,000 patients but less than 1 in 100 patients, include swelling of the face and body, feeling faint, cold fingers and toes,, dizziness on standing, a racing or irregular heart beat, a slow heart beat, angina, severe chest pain, difficulty breathing, tremor, muscle stiffness, weakness or pain, pain or swelling of joints, change in appetite, hair loss, nose bleeds, cough, sore swollen throat, low blood potassium levels, feeling thirsty, gout, nightmares, loss of memory, mood changes, loss of bladder control or less frequent urge to pass urine, ringing in the ears and changes in taste.
Kolloidalt vandfrit silica Natriumstearylfumarat 
Silica, colloidal anhydrous Sodium stearyl fumarate
LÆGEMIDLETS NAVN Doxagamma 4 mg depottabletter og dermed forbundne navne [se Bilag I] Doxazosin NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN [Udfyldes nationalt] UDLØBSDATO Udløbsdato: BATCHNUMMER 
NAME OF THE MEDICINAL PRODUCT Doxagamma 4 mg prolonged release tablets and associated names [See Annex I] doxazosin NAME OF THE MARKETING AUTHORISATION HOLDER [To be completed nationally] EXPIRY DATE
Behandling med doxazosin hos patienter med nedsat leverfunktion bør udføres med forsigtighed (se pkt. 
Doxazosin therapy in patients with hepatic impairment should be performed with caution (see section 4.4).
Sjældne bivirkninger, der ses hos flere end 1 patient ud af 10.000. menn færre end 1 ud af 1.000, omfatter depression, følelse af rastløshed, stikken og prikken, et allergisk udslæt, kløende rød hud, mavesmerter, diaré, værende syg, en hæs stemme, besvimelse, tab af bevidsthed, gulsot, leverforandringer, lavt blodsukker, impotens, vedvarende erektion. 
Rare side effects, seen in more than 1 in 10,000 patients but less than 1 out of 1,000, include depression, feeling restless, pins and needles, an allergic rash, itchy red skin, stomach pain, diarrhoea, being sick, a hoarse voice, fainting, loss of consciousness, jaundice, liver changes, low blood sugar, impotence, persistent erection.
Almindelig: Svimmelhed, ødem, ortostatisk fejlregulering Usædvanlig: Postural hypotension, perifer iskæmi, synkope Sjælden: Cerebrovaskulære forstyrrelser 
Common: giddiness, dizziness, oedema, orthostatic dysregulation Uncommon: postural hypotension, peripheral ischaemia, syncope Rare: cerebrovascular disturbances
SAMLET RESUMÉ AF DEN FAGLIGE VURDERING AF Doxagamma 4 mg depottabletter og de tilknyttede navne ( se bilag I) 
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF Doxagamma 4 mg prolonged release tablets and associated names (see Annex I)
Doxagamma 4 mg depottabletter og dermed forbundne navne er kontraindicerede under amning, da lægemidlet akkumuleres i mælken hos ammende rotter (se pkt. 
Doxagamma 4 mg prolonged release tablets and associated names is contraindicated during lactation as the medicinal product accumulates in the milk of lactating rats (see section 5.3) and there is no information about the excretion of the medicinal product into human breast milk.
6.6 Særlige forholdsregler ved bortskaffelse Ingen særlige forholdsregler. 
Pack sizes: 100, 250 tablets Not all pack sizes may be marketed 6.6 Special precautions for disposal No special requirements.
• Tabletterne må ikke tygges, brækkes over eller knuses 
• Do not chew, break or crush the tablets.
INDLÆGSSEDDEL: INFORMATION TIL BRUGEREN Doxagamma 4 mg depottabletter og dermed forbundne navne [se Bilag I] (Doxazosin) 
PACKAGE LEAFLET: INFORMATION FOR THE USER Doxagamma 4 mg prolonged release tablets and associated names [See Annex I] (Doxazosin)
LÆGEMIDLETS NAVN Doxagamma 4 mg depottabletter og dermed forbundne navne [se Bilag I] doxazosin ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver depottablet indeholder 4 mg doxazosin (som mesilat). 
NAME OF THE MEDICINAL PRODUCT Doxagamma 4 mg prolonged release tablets and associated names doxazosin STATEMENT OF ACTIVE SUBSTANCE(S) Each prolonged-release tablet contains 4 mg of doxazosin (as mesylate).
Anvend Doxagamma 4 mg depottabletter og de dermed forbundne navne ikke efter udløbsdato, som er angivet på blisterpakningen. 
Do not use Doxagamma 4 mg prolonged release tablets and associated names after the expiry date which is stated on the blister and carton.
butylhydroxytoluen (E321), α-Tocopherol, kolloidalt vandfrit silica, natriumstearyl fumarat, 
(E321), alpha-tocopherol, anhydrous colloidal silica, sodium stearyl fumarate, methacrylic acid copolymer and titanium dioxide (E171)
Almindelig: Hyppigt ønske om at lade vandet, øget vandladning, sen ejakulation Usædvanlig: Inkontinens, vandladningsforstyrrelser, dysuri Sjælden: impotens, priapisme 
Common: frequent desire to micturate, increased micturation, delayed ejaculation Uncommon: incontinence, micturation disturbances, dysuria Rare: impotence, priapism
1 HVAD DOXAGAMMA 4 MG DEPOTTABLETTER OG DERMED FORBUNDNE NAVNE NAVNE ER, OG HVAD DE ANVENDES TIL 
1 WHAT DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES IS AND WHAT IT IS USED FOR
Doxazosin bør gives med særlig forsigtighed til patienter med tegn på nedsat leverfunktion. 
Patients with hepatic impairment: Doxazosin should be given with particular caution to patients with evidence of impaired liver function.
1 LÆGEMIDLETS NAVN Doxagamma 4 mg depottabletter og dermed forbundne navne [se Bilag I] 
1 NAME OF THE MEDICINAL PRODUCT Doxagamma 4 mg prolonged release tablets and associated names [See Annex I]
8 MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) [Udfyldes national] 
8 MARKETING AUTHORISATION NUMBER [To be completed nationally]
Doxagamma 4 mg depottabletter og dermed forbundne navne [se Bilag I] Doxazosin 
Doxagamma 4 mg prolonged release tablets and associated names {See Annex I] doxazosin
Depottabletterne bør ikke tygge, dele eller knuse tabletten. 
The prolonged-release tablets should not be chewed, divided or crushed.
Depottablet 
- Lactation
Usædvanlig: Epistaxi, bronkospasmer, hoste, faryngit Sjælden: Larynxødem 
Uncommon: epistaxis, broncho spasms, cough, pharyngitis Rare: oedema of larynx
Depottabletter oral anvendelse 
Oral use
Almindelige bivirkninger, der ses hos mere end 1 patient ud af 100, omfatter: Svimmelhed, følelse af usædvanlig træthed eller alem utilpashed, opsvulmen af anklerne, palpitationer, hoved pine, brystsmerter, søvninghed, muskelkramper, konstipation, fordøjelsesbesvær, åndenød, løbende næse, forsinket ejakulation, hyppig trang til at lade vandet og sløret syn. 
Common side effects, seen in more than 1 in 100 patients but less than 1in 10, include dizziness, giddiness, feeling unusually tired or generally unwell, swelling of the ankles, palpitations, headache, chest pain, sleepiness, muscle cramp, constipation, indigestion, breathlessness, runny nose, delayed ejaculation, frequent urge to pass urine and blurred vision.
Sygdomme i lever og galdeveje: Sjælden: Ikterus, forhøjede levertal 
Hepato-biliary disorders: Rare: icterus, increased liver values
anbefaler CPMP, at der udstedes markedsføringstilladelse(r) for Doxagamma 4 mg depottabletter og de tilknyttede navne (se bilag I). 
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxagamma 4 mg prolonged release tablets and associated names (see Annex I).